Filing Flows › Comparisons › CTMX vs ALMS
CytomX Therapeutics vs Alumis: CTMX and ALMS compared
CytomX Therapeutics is the larger company: $1.7M of revenue in its latest quarter (Q3 2026) against $1.7M for Alumis (Q2 2026). Alumis is growing faster (-38% against -72% a year earlier).
Where the money goes: CTMX and ALMS
CytomX Therapeutics (CTMX) · Q3 2026
CytomX Therapeutics, Q3 2026: revenue $1.7M (-72% year over year), net loss $20.0M, operating cash flow $16.6M. The chart follows the revenue to costs, profit and cash.
Alumis (ALMS) · Q2 2026
Alumis, Q2 2026: revenue $1.7M (-38% year over year), net loss $142M, operating cash flow −$81.5M. The chart follows the revenue to costs, profit and cash.
| CytomX Therapeutics (CTMX) | Alumis (ALMS) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $1.7M | $1.7M |
| Revenue growth, Y/Y | -72% | -38% |
| Operating margin | n/m | n/m |
| Net earnings | −$20.0M | −$142M |
| Operating cash flow | $16.6M | −$81.5M |
| Free cash flow | $16.1M | — |
Questions
Which is bigger, CytomX Therapeutics or Alumis?
CytomX Therapeutics is the larger company: $1.7M of revenue in its latest quarter (Q3 2026) against $1.7M for Alumis (Q2 2026).
Is CytomX Therapeutics or Alumis growing faster?
Alumis is growing faster (-38% against -72% a year earlier).
More: CytomX Therapeutics earnings · how CytomX Therapeutics makes money · Alumis earnings · how Alumis makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.